Cosette Pharmaceuticals Launches Metronidazole Vaginal Gel 0.75%, AB-rated to MetroGel-Vaginal® 0.75%
Further expands Cosette’s portfolio in affordable women’s healthcare…
EY Announces Apurva Saraf, President and CEO of Cosette Pharmaceuticals as an Entrepreneur Of The Year® 2023 New Jersey Award Winner
Bridgewater, June 14, 2023 – Ernst & Young LLP (EY US) today announced that…
Cosette Pharmaceuticals Acquires Intrarosa® from Endoceutics, Inc.
Acquisition accelerates Cosette’s women’s health portfolio; with a…
Jackie Beltrani Joins Cosette Pharmaceuticals as Director, Commercial Operations.
We are pleased to announce that Jackie Beltrani has joined Cosette…
Cosette Pharmaceuticals Launches Betaine Anhydrous Powder, AB-rated to Cystadane® (betaine anhydrous for oral solution)
Launch offers important and affordable alternative for patients Bridgewater,…
Cosette Pharmaceuticals Announces the Approval and Launch of Metronidazole Gel USP, 1%.
Launch Expands Cosette’s Generic Portfolio Through Organic Development…
Cosette Pharmaceuticals Announces the launch of Griseofulvin Oral Suspension, 125 mg/5 mL.
Launch Enables Access To Patients And Providers, Alleviating Supply Chain…
Cosette Pharmaceuticals Appoints Kevin Hickey, Vice President, Brand Sales and Marketing to Accelerate Transformation
Experienced sales and marketing executive Kevin Hickey will build on and…
Cosette Pharmaceuticals Announces the Approval and Launch of First Generic Versions of TAZORAC® (tazarotene) gel, 0.05% and 0.1%, with 180 days Competitive Generic Therapy (CGT) exclusivity
Bridgewater, NJ, United States. September 20, 2022. Cosette Pharmaceuticals,…
Ganesh Pillarisetti has joined Cosette Pharmaceuticals as Vice President, IT
We are pleased to announce Ganesh Pillarisetti has joined the executive team as…